Open AccessSeverity of COVID-19 in bacillus Calmette-Guérin vaccinated population
Author(s) -
Iffat Khanum,
Lalit Kumar,
Safia Awan,
Bushra Jamil
Publication year - 2021
Publication title -
clinical and experimental vaccine research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.958
H-Index - 11
eISSN - 2287-366X
pISSN - 2287-3651
DOI - 10.7774/cevr.2021.10.3.276
Subject(s) - medicine , vaccination , bcg vaccine , pneumonia , population , immunology , coronavirus , disease , covid-19 , infectious disease (medical specialty) , environmental health
Considering the cross-protection reported for bacillus Calmette-Guérin (BCG) vaccination on viral respiratory infections, it has been proposed that it could reduce the severity of coronavirus disease 2019 (COVID-19). The objective of the current study is to investigate the association between the severity of COVID-19 with prior BCG vaccination in adult patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.